PO.TB03.05 · 肿瘤生物学
SUMO化调控GATA2稳定性以控制子宫浆液性癌的侵袭
SUMOylation regulates GATA2 stability to control uterine serous carcinoma invasion
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:子宫浆液性癌(USC)是一种侵袭性子宫癌亚型,占子宫癌死亡的40%。我们最近证明,USC丧失锌指转录因子GATA2的表达,该丧失驱动USC侵袭、预测USC复发,并与不良的癌症相关生存和总生存密切相关。然而,USC中GATA2下调的机制基础仍不明确。
方法:将GATA2 RNA转录本与来自癌症基因组图谱(TCGA)的患者结局相关联。通过亚硫酸氢盐测序在从患者USC肿瘤中分离的基因组DNA中评估GATA2基因甲基化。使用Ark1和Ark2 USC细胞系进行体外研究。使用环己酰亚胺追踪实验,配合磷酸化抑制剂(staurosporine)、乙酰化抑制剂(C646)、SUMO化抑制剂(ML792)、半胱氨酸肽酶活性抑制剂(N-乙基马来酰亚胺/NEM)和蛋白酶体依赖性降解抑制剂(MG132),测定GATA2的半衰期。使用定制的抗GATA2抗体(Im等,2005)进行抗GATA2免疫沉淀。使用市售siRNA对PIAS2、SENP1和SUMO2/3进行耗竭。通过western blot测定GAPDH、GATA2、PIAS2、SENP1和SUMO2/3的水平。使用Matrigel包被膜的transwell插入物评估USC侵袭。
结果:GATA2 IHC蛋白水平与GATA2基因体或近端启动子DNA甲基化无相关性,且GATA2转录本水平在TCGA USC病例中不能预测患者结局。在翻译后水平,USC GATA2蛋白在环己酰亚胺处理后半衰期约为60分钟。与SUMO化抑制剂ML792或蛋白酶体抑制剂MG132共处理与溶媒相比延长了GATA2半衰期,而抑制去SUMO化和去泛素化的NEM处理则缩短了GATA2半衰期。通过抗GATA2免疫沉淀和SUMO2/3 western blot证实了GATA2的直接SUMO化。基于候选siRNA的方法发现,E3 SUMO连接酶PIAS2的耗竭升高了GATA2水平,而SUMO肽酶SENP1的耗竭则降低了GATA2水平。siRNA介导的SUMO2/3耗竭在USC细胞中显著增加了GATA2水平,并与siScramble对照相比在体外抑制了USC侵袭。
结论:USC GATA2水平由翻译后机制决定。GATA2蛋白具有由SUMO化和蛋白酶体介导的降解所决定的约60分钟的快速半衰期。耗竭实验支持PIAS2为靶向GATA2的E3 SUMO连接酶、SENP1为靶向GATA2的SUMO肽酶。SUMO抑制增加了USC GATA2水平并抑制了USC侵袭,提示靶向SUMO的药物可能通过上调GATA2水平来抑制USC扩散。
查看英文原文 English abstract
Background: Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that is responsible for 40% of uterine cancer deaths. We recently demonstrated that USCs lose expression of the zinc-finger transcription factor GATA2 which drives USC invasion, predicts USC recurrence, and is closely correlated with poor cancer-related and overall survival. However, the mechanistic basis of GATA2 downregulation in USC remains unknown.
Methods: GATA2 RNA transcripts were correlated to patient outcomes derived from The Cancer Genome Atlas (TCGA). GATA2 gene methylation was assessed in isolated genomic DNA from patient USC tumors by bisulfite sequencing. Ark1 and Ark2 USC cell lines were utilized for in vitro studies. GATA2 half-life was measured using cycloheximide chase experiments paired with inhibitors of phosphorylation (staurosporine), acetylation (C646), SUMOylation (ML792), cysteine peptidase activity (N-Ethylmaleimide/NEM), and proteasome-dependent degradation (MG132). Anti-GATA2 immunoprecipitations were performed with custom anti-GATA2 antibodies (Im et al, 2005). Depletion of PIAS2, SENP1, and SUMO2/3 was performed using commercially available siRNAs. Levels of GAPDH, GATA2, PIAS2, SENP1, and SUMO2/3 were measured by western blotting. USC invasion was assessed using Matrigel-coated membrane transwell inserts.
Results: GATA2 IHC protein levels showed no correlation with GATA2 gene body or proximal promoter DNA methylation, and GATA2 transcript levels did not predict patient outcome across TCGA USC cases. Post-translationally, USC GATA2 protein half-life was approximately 60 minutes after cycloheximide treatment. Co-treatment with the SUMOylation inhibitor ML792 or the proteasome inhibitor MG132 prolonged GATA2 half-life compared with vehicle, whereas NEM treatment, which inhibits de-SUMOylation and de-ubiquitination, shortened GATA2 half-life. Direct GATA2 SUMOylation was confirmed by anti-GATA2 immunoprecipitation and SUMO2/3 western blot. A candidate siRNA-based approach found that depletion of the E3 SUMO ligase PIAS2 elevated GATA2 levels, while depletion of the SUMO peptidase SENP1 reduced GATA2 levels. siRNA-mediated SUMO2/3 depletion significantly increased GATA2 levels in USC cells and suppressed USC invasion in vitro compared to siScramble controls.
Conclusion: USC GATA2 levels are determined by post-translational mechanisms. GATA2 protein has a rapid 60-minute half-life determined by SUMOylation and proteasome-mediated degradation. Depletion experiments support PIAS2 as the GATA2-targeting E3 SUMO ligase and SENP1 as the GATA2-targeting SUMO peptidase. SUMO inhibition increased USC GATA2 levels and suppressed USC invasion, suggesting that SUMO-targeting agents may suppress USC spread through upregulation of GATA2 levels.
利益披露 Disclosure
A. A. Mattix, None..
P. Liu, None..
M. A. Accola, None..
W. M. Rehrauer, None..
D. R. Matson, None.